Vaxart, Inc.
No SEC Form 4 filings for $VXRT in the last 30 days.
See all $VXRT insider activity →Vaxart reported 100% survival and reduced viral load in ferrets for its oral H5N1 vaccine candidate VXA-H5-02, according to peer-reviewed preclinical data. The company has not yet tested the vaccine in humans.
Vaxart, Inc. (VXRT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vaxart Provides Business Update and Reports Second Quarter 2026 Financial Results Reported topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial; Topline data from 400-person sentinel safety cohort and approximately 5,000 participants in main co
Vaxart, Inc. (VXRT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. vxrt20260717_8k.htm false 0000072444 0000072444 2026-07-16 2026-07-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event repo
Over the past 7 days, AlphAI's AI scored 1 news story mentioning VXRT (Vaxart, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent VXRT coverage spans corporate actions, financial news and earnings.
Positive preclinical results may boost investor sentiment and raise expectations for upcoming IND filing.
Clinical milestone plus cash runway guidance and BARDA funding modification can shift near-term risk perception and financing expectations.
Routine shareholder voting outcomes with no new financial guidance or corporate action beyond governance confirmations.
Safety profile looks clean at 12 months versus an XBB mRNA comparator, but efficacy remains unpowered and full data are deferred to 2027.
The 8-K discloses a negotiated settlement with a stockholder group that ends a contested board/proxy effort and sets a process to add a new independent director.
AlphAI scores every news story that mentions VXRT with an AI model for sentiment and relevance, and aggregates insider trades from Vaxart, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Vaxart reported 100% survival and reduced viral load in ferrets for its oral H5N1 vaccine candidate VXA-H5-02, according to peer-reviewed preclinical data. The company has not yet tested the vaccine in humans.
1 min readVaxart, Inc. (VXRT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vaxart Provides Business Update and Reports Second Quarter 2026 Financial Results Reported topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial; Topline data from 400-person sentinel safety cohort and approximately 5,000 participants in main co
6 min readVaxart, Inc. (VXRT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. vxrt20260717_8k.htm false 0000072444 0000072444 2026-07-16 2026-07-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event repo
2 min readVaxart (VXRT) reported 12-month topline safety results from a 400-participant Phase 2b sentinel cohort comparing its oral COVID-19 pill to an approved XBB-targeting mRNA vaccine. No vaccine-related serious adverse events or sustained Grade 3+ events occurred. Common oral side effects included malaise/fatigue (20.9%) and headache (18.9%); mRNA had higher injection-site reactions. Full data expected in 2027.
2 min readVaxart, Inc. (VXRT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ea029670901ex10-1.htm COOPERATION AGREEMENT, DATED JULY 1, 2026 Exhibit 10.1 COOPERATION AGREEMENT This COOPERATION AGREEMENT (this “ Agreement ”) is made and entered into as of July 1, 2026, by and among Vaxart, Inc., a Delaware corporation (the “ Company ”), on the on
4 min readVaxart, Inc. (VXRT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. vxrt20260626_8k.htm false 0000072444 0000072444 2026-06-22 2026-06-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event repo
4 min readVaxart said it modified its BARDA funding contract via Advanced Technology International to match the current scope of its Phase 2b COVID-19 oral pill vaccine trial. Total available funding is now about $345 million, down ~$116 million after a BARDA partial termination reduced enrollment. The change releases ~$29 million to complete trial and exploratory analyses, enabling 12-month sentinel-cohort data in coming weeks and main-cohort data in 1H 2027.
3 min readWatson W. Mark purchased 10,000 shares of Vaxart, Inc. (VXRT) at $0.65 on 2026-05-22.
1 min readVaxart, Inc. (VXRT) has announced it will terminate its headquarters lease early in South San Francisco, effective May 15, 2026, as part of cost-reduction efforts. The biotech company, despite a recent revenue increase, is quickly burning through cash and plans to relocate to another existing office in the South San Francisco area. This decision comes as the company aims to address operational challenges and improve its financial efficiency.
3 min readThird quarter 2025 results conference call to be held on November 13 at 4:30 p.m. ET ...
2 min read
